1. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China
- Author
-
Renfang Zhang, Jingna Xun, Jiangrong Wang, Hongzhou Lu, Jun Chen, Corklin Steinhart, Danping Liu, Li Liu, and Yinzhong Shen
- Subjects
Adult ,Male ,China ,medicine.medical_specialty ,Hepatitis C virus ,HIV Infections ,medicine.disease_cause ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Internal medicine ,Epidemiology ,Nonalcoholic fatty liver disease ,Prevalence ,medicine ,Humans ,Mass Screening ,Hepatitis B virus ,Hepatology ,business.industry ,Fatty liver ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Cross-Sectional Studies ,030220 oncology & carcinogenesis ,Elasticity Imaging Techniques ,Female ,030211 gastroenterology & hepatology ,Transient elastography ,business - Abstract
BACKGROUND AND AIM The new definition for metabolic associated fatty liver disease (MAFLD), formerly named non-alcoholic fatty liver disease (NAFLD), would undoubtedly have significant influence on diagnosis, epidemiology, and new drug research. We investigated the prevalence and risk factors of MAFLD among people living with HIV (PLWH). METHODS In this cross-sectional study, transient elastography was performed in PLWH without significant alcohol intake and hepatitis B virus and hepatitis C virus infection. NAFLD was diagnosed as controlled attenuation parameter (CAP) ≥ 248 dB/m by transient elastography, and MAFLD was defined according to the 2020 international consensus. Advanced fibrosis was defined as liver stiffness measurement (LSM) ≥ 10 kPa. RESULTS Among the 361 PLWH enrolled, the prevalence of NAFLD and MAFLD were 37.67% and 34.90%, respectively. Compared with the non-MAFLD group, the prevalence of elevated alanine aminotransferase (ALT) level (44.44% vs 16.17%, P
- Published
- 2021